OncoTherapy Science, Inc. (4564.T) Comparison with companies in other sectors?

OncoTherapy Science, Inc. has a share price of 304.64M. You can analyze OncoTherapy Science, Inc. (4564.T) competitors across different market sectors through stock heatmaps.

What are 4564.T's NET and operating margins?

OncoTherapy Science, Inc. (4564.T) operating margin is around -1.09, and net profit margin is approximately -1.09 as of the latest reports.

In what way does 4564.T's earnings per share (EPS) trend reflect its financial momentum?

OncoTherapy Science, Inc. (4564.T) EPS is -3.12 (If EPS value is positive, then “signals consistent profit growth” if Negative then “signals consistent loss”). This metric is also critical in assessing valuation metrics like the P/E ratio for OncoTherapy Science, Inc. is -9.29, and the company’s ability to reinvest or distribute profits.

What does a high ROE mean for OncoTherapy Science, Inc.?

A high ROE suggests efficient use of shareholder equity to generate profit. It often signals strong management and profitability.

How do I know if AAPL is overvalued or undervalued?

Check valuation ratios for OncoTherapy Science, Inc. like P/E which is -9.66, P/B which is 10.80, and PEG which is -0.40. Compare them with sector averages to evaluate if the stock is priced fairly.

OncoTherapy Science, Inc.

4564.T•JPX

Healthcare

Biotechnology

¥28.00

¥-1.00(-3.45%)

OncoTherapy Science, Inc. (4564.T) Fundamental Analysis: Financial Health, Valuation, and Key Ratios

Dive into Apple Inc.’s fundamentals including valuation ratios, profitability, efficiency metrics, and financial health. Use this data to assess long-term investment quality and compare it with sector benchmarks.

EPS (TTM)

$-3.12

P/E Ratio

-9.29

ROE

-1.00%

Net Margin

-1.09%

Key Financial Metrices

Valuation Metrics

4 metrics

Market CapTotal market value of outstanding shares

$8.83B

Shares OutstandingTotal number of shares issued

$304.64M

Book Value/ShareNet worth per share

$2.69

Revenue/ShareAnnual revenue per share

$2.76

Profitability Metrics

6 metrics

EPS (TTM)Earnings per share trailing twelve months

$-3.12

Net MarginNet income as percentage of revenue

-108.71%

Operating MarginOperating income as percentage of revenue

-108.81%

ROEReturn on shareholders' equity

-99.56%

ROAReturn on total assets

-70.55%

ROCEReturn on capital employed

-98.59%

Cash Flow Metrics

3 metrics

Free Cash Flow/ShareCash generated per share after capex

Cash/ShareCash and equivalents per share

$3.07

FCF YieldFree cash flow as percentage of market cap

Dividend Metrics

2 metrics

Dividend/ShareAnnual dividend payment per share

Dividend YieldAnnual dividend as percentage of stock price

Financial Ratios Analysis data is not available for 4564.TFinancial Ratios Analysis details for 4564.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Sector Benchmarking data is not available for 4564.TSector Benchmarking details for 4564.T are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.

Understanding Fundamental Analysis for OncoTherapy Science, Inc. Investment Decisions

What is Fundamental Analysis?

Fundamental analysis is a method used to assess the intrinsic value of OncoTherapy Science, Inc.. Using financial reports, management structure, competitive position, and market environment, investors can determine whether the stock is undervalued or overvalued. This analysis helps investors like you make more informed investment decisions, taking into account OncoTherapy Science, Inc.'s unique business strengths and challenges.

Key Financial Metrics for OncoTherapy Science, Inc.

For OncoTherapy Science, Inc., essential financial indicators include EPS -3.12, PE -9.29, and ROE -1.00. These key ratios reveal insights into OncoTherapy Science, Inc.'s profitability, valuation, and operational health. Understanding these metrics enables you to compare OncoTherapy Science, Inc. with its industry peers and decide whether it presents a viable investment opportunity.

Profitability and Operational Efficiency of OncoTherapy Science, Inc.

Metrics like Net Margin -108.71% and ROA -70.55% shed light on how well OncoTherapy Science, Inc. is generating profits. A high profitability ratio often indicates strong management and a solid business model, which are essential for long-term growth. These metrics are crucial in assessing whether OncoTherapy Science, Inc. can sustain its operations and continue growing in the future.

Valuation and Market Position of OncoTherapy Science, Inc.

Using ratios such as P/B Ratio 10.80 and PEG Ratio -0.40, investors can assess whether OncoTherapy Science, Inc. is appropriately valued based on its financials and growth potential. These figures, combined with OncoTherapy Science, Inc.'s market capitalization, give insight into its competitive positioning and investor expectations, helping you make informed decisions on pricing and value.

Financial Health and Risk Assessment for OncoTherapy Science, Inc.

Financial health indicators, such as Debt/Equity Ratio 0.07 and Cash Flow -, provide a snapshot of OncoTherapy Science, Inc.'s ability to meet financial obligations and handle economic setbacks. A company with a strong balance sheet and solid cash flow, like OncoTherapy Science, Inc., is more likely to weather financial storms, making it a safer investment.

Long-Term Investment Strategy for OncoTherapy Science, Inc.

Investing in OncoTherapy Science, Inc. based on fundamental analysis emphasizes long-term business growth rather than short-term market trends. Investors looking at OncoTherapy Science, Inc. focus on its solid financial performance, industry standing, and competitive advantages, all of which suggest sustainable growth and the potential for steady returns over time.

Fundamental Analysis FAQ

;